Cryptococcal chest wall mass and rib osteomyelitis associated with the use of fingolimod: A case report and literature review

Cryptococcal chest wall mass and rib osteomyelitis associated with the use of fingolimod: A case report and literature review

Being introduced in 2010, fingolimod was among the first oral therapies for relapsing multiple sclerosis (MS). Since that time, postmarketing surveillance has noted several case reports of various cryptococcal infections associated with fingolimod use. To date, approximately 15 such case reports hav...

Full description

Bibliographic Details
Main Authors: Kent Carpenter, Ali Etemady-Deylamy, Victoria Costello, Mohammad Khasawneh, Robin Chamberland, Katherine Tian, Maureen Donlin, Brenda Moreira-Walsh, Emily Reisenbichler, Getahun Abate
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Medicine
Subjects:
cryptococcus
fingolimod
chest mass
osteomyelitis
immunosuppression
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.942751/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.942751/full

Similar Items